These studies suggest plausibility but not confirmation
Most of the studies have been done on rats, and its not clear if the benefits apply to humans
Overall, site location and choosing the appropriate vein are usually based on the type of treatment involved and how long the infusion will last
IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) is a modified analogue of human IGF-1 with an extended half-life due to an arginine substitution at position 3 and a 13-amino-acid N-terminal extension that reduces binding to IGF-binding proteins
In the present study, suboptimal functional recovery was perhaps due to insufficient axon growth, improper alignment of the nerve fascicles following nerve transection-repair and other unknown factors [17,26,29,34,57,63,77]